NovaBridge Biosciences is a clinical-stage global biotechnology company developing differentiated biologics for cancer and retinal diseases. Its lead programs include givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB in clinical trials for gastric cancer, and VIS-101, a bifunctional biologic for wet age-related macular degeneration and diabetic macular edema. The company leverages partnerships with pharmaceutical companies to advance its pipeline of immuno-oncology and ophthalmology assets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -9.1 | — |
| Q1 2025 | 0 | — | -3.1 | — |
| Q2 2025 | 0 | — | -5.5 | — |
| Q3 2025 | 0 | — | -6.8 | — |
| Q4 2025 | 0 | — | -30.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pro-Dex, Inc. (PDEX), QuickLogic Corporation (QUIK), Translational Development Acquisition Corp. (TDAC), AN2 Therapeutics, Inc. (ANTX), Journey Medical Corporation (DERM), Oramed Pharmaceuticals Inc. (ORMP)